Sirukumab

Sirukumab is a monoclonal antibody designed for the treatment of rheumatoid arthritis. It was developed by Janssen Biotech, a pharmaceutical company that is a division of Johnson & Johnson. Sirukumab works by targeting the interleukin-6 (IL-6) cytokine, which plays a key role in the inflammatory process of rheumatoid arthritis.

Development and Clinical Trials

The development of Sirukumab began in the early 2000s, with the aim of finding a more effective treatment for rheumatoid arthritis. The drug was designed to bind to the IL-6 cytokine, thereby inhibiting its function and reducing inflammation.

In 2017, the Food and Drug Administration (FDA) rejected the application for Sirukumab, citing concerns about safety and efficacy. The FDA requested additional data to further evaluate the safety and benefit-risk profile of the drug.

Mechanism of Action

Sirukumab is a monoclonal antibody that binds to the IL-6 cytokine. IL-6 is a protein produced by various cells in the body, including immune cells, and is involved in the inflammatory response. By binding to IL-6, Sirukumab prevents it from interacting with its receptor, thereby inhibiting the inflammatory response that contributes to the symptoms of rheumatoid arthritis.

Potential Side Effects

As with all medications, Sirukumab has the potential to cause side effects. These can include infections, neutropenia (a decrease in the number of white blood cells), and abnormalities in liver function tests. It is important for patients to discuss these potential risks with their healthcare provider before starting treatment with Sirukumab.

Future Research

Despite the initial rejection by the FDA, research into Sirukumab continues. Scientists are hopeful that with further study, they can address the FDA's concerns and eventually bring this promising treatment to patients with rheumatoid arthritis.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!